[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352104-105":59,"doc-detail-352104-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inflammatory-and-immune-microenvironment-in-myeloproliferative-neoplasms-pathogenic-mechanisms-and-therapeutic-opportunities","Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms - Pathogenic Mechanisms and Therapeutic Opportunities","","Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) comprise polycythemia vera, essential thrombocythemia, and primary myelofibrosis, driven by somatic JAK2, CALR, or MPL mutations. These lesions activate JAK–STAT and disturb NF-κB signaling, establishing chronic inflammatory and oxidative environments that promote fibrosis, splenomegaly, vascular niche remodeling, thrombosis, and occasional leukemic transformation. Concurrent immune dysfunction includes T and B cell exhaustion, impaired NK maturation, and accumulation of myeloid-derived suppressor cells. JAK1/JAK2 inhibitors improve symptoms and spleen size but rarely eradicate malignant clones, motivating emerging strategies targeting inflammatory and immune mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inflammatory-and-immune-microenvironment-in-myeloproliferative-neoplasms-pathogenic-mechanisms-and-therapeutic-opportunities/352104/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inflammatory-and-immune-microenvironment-in-myeloproliferative-neoplasms-pathogenic-mechanisms-and-therapeutic-opportunities/352104.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What genetic alterations drive Philadelphia-negative myeloproliferative neoplasms?","Question",{"text":112,"@type":113},"Ph-negative MPNs are caused by somatic mutations in JAK2, CALR, or MPL, which activate signaling pathways involved in inflammation and abnormal hematopoiesis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the inflammatory microenvironment contribute to disease complications?",{"text":117,"@type":113},"The altered microenvironment promotes chronic inflammation and oxidative stress, contributing to bone marrow fibrosis, splenomegaly, vascular remodeling, thrombosis, and in some patients progression to acute leukemia.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do current JAK1/JAK2 inhibitors not fully control Ph-negative MPNs?",{"text":121,"@type":113},"Although ruxolitinib and related agents can reduce splenomegaly and symptoms and may improve survival, they generally do not eliminate malignant clones or reliably prevent disease progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352104,1790604289,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review  \nInflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities  \nFaride Kaikavoosnejad 1, Ali Keyhani 1, Seyyede Sepide Ashraf Moosavi 1, Milad Verdi 1, Mohammad Sepehr Yazdani 1, Khadijeh Dizaji Asl 2, Zeinab Mazloumi 3, Hamed Mirzaei 4, Ali Rafat 5, * and Reza Nejati 6, *  \nAcademic Editor: Bojana Beleslin ˇCoki´c  \nReceived: 22 June 2026  \nRevised: 13 August 2026  \nAccepted: 19 August 2026  \nPublished: 21 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran, 8715988141; [keikavoosnejad-f@kaums.ac.ir](keikavoosnejad-f@kaums.ac.ir) (F.K.); [keyhani-ali@kaums.ac.ir](keyhani-ali@kaums.ac.ir) (A.K.);  \n[ashrafmousavi-s@kaums.ac.ir](ashrafmousavi-s@kaums.ac.ir) (S.S.A.M.); [miladvrd@gmail.com](miladvrd@gmail.com) (M.V.); [mr.msyazdani@gmail.com](mr.msyazdani@gmail.com) (M.S.Y.)  \n2 Department of Histopathology and Anatomy, TaMS.C., Islamic Azad University, Tabriz, Iran, 5157944533; [kh.dizaji@iau.ac.ir](kh.dizaji@iau.ac.ir)  \n3 Department of Medical Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran, 5166614711; [mazloomi@tbzmed.ac.ir](mazloomi@tbzmed.ac.ir)  \n4 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran, 8715988141; [mirzaei-h@kaums.ac.ir](mirzaei-h@kaums.ac.ir)  \n5 Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran, 8715988141  \n6 Department of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA  \n* Correspondence: [rafata@tbzmed.ac.ir](rafata@tbzmed.ac.ir) (A.R.); [reza.nejati@fccc.edu](reza.nejati@fccc.edu) (R.N.)  \nSimple Summary  \nPhiladelphia-negative myeloproliferative neoplasms (Ph-negative MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are blood cancers driven mainly by mutations in the JAK2, CALR, or MPL genes. These mutations alter cellular signaling and promote persistent inflammation through increased production of inflammatory molecules and reactive oxygen species. This inflammatory environment contributes to bone marrow fibrosis, splenomegaly, vascular changes, thrombosis, and, in some patients, progression to acute leukemia. MPNs also disrupt the immune system, leading to impaired T-and B-cell function, abnormal Natural Killer cell maturation, and accumulation of immunosuppressive myeloid-derived suppressor cells. Although JAK1/JAK2 inhibitors can reduce symptoms and spleen enlargement and may improve survival, they generally do not eliminate malignant cells or prevent disease progression. Current treatment strategies therefore remain focused largely on controlling disease manifestations while emerging therapeutic approaches aim to target the inflammatory and immune mechanisms that contribute to disease progression.  \nAbstract  \nPhiladelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which are clonal hematopoietic disorders caused by somatic gene mutations in the JAK2, CALR, or MPL genes. Mutations activate the JAK–STAT pathway and disrupt NF-κB signaling, leading to a chronic inflammatory state caused by pro-inflammatory cytokines and reactive oxygen species (ROS) . This altered microenvironment causes serious clinical features of the disease, such as bone marrow fibrosis, splenomegaly, vascular niche remodeling, and a greater probability of thrombosis or secondary leukemic transformation. Concurrently, MPNs cause both severe immune dysregulation and tumor evasion,  \nas evidenced by progressive ","cbCaiadVqL3VfEWe","https://ap.wps.com/l/cbCaiadVqL3VfEWe","pdf",2832137,29,"English","# 1. Introduction\n## Philadelphia-negative MPNs and key subtypes\n## Epidemiology and classification context\n# 2. Pathogenic mechanisms in the inflammatory and immune microenvironment\n## JAK–STAT and NF-κB signaling alterations\n## Inflammation, ROS, and disease manifestations\n# 3. Immune dysregulation and tumor evasion\n## T and B cell exhaustion and NK maturation arrest\n## Myeloid-derived suppressor cell accumulation\n# 4. Therapeutic opportunities and emerging precision targets\n## Limitations of JAK1/JAK2 inhibitors\n## Rationale for targeting inflammatory and immune pathways","[{\"question\":\"What genetic alterations drive Philadelphia-negative myeloproliferative neoplasms?\",\"answer\":\"Ph-negative MPNs are caused by somatic mutations in JAK2, CALR, or MPL, which activate signaling pathways involved in inflammation and abnormal hematopoiesis.\"},{\"question\":\"How does the inflammatory microenvironment contribute to disease complications?\",\"answer\":\"The altered microenvironment promotes chronic inflammation and oxidative stress, contributing to bone marrow fibrosis, splenomegaly, vascular remodeling, thrombosis, and in some patients progression to acute leukemia.\"},{\"question\":\"Why do current JAK1/JAK2 inhibitors not fully control Ph-negative MPNs?\",\"answer\":\"Although ruxolitinib and related agents can reduce splenomegaly and symptoms and may improve survival, they generally do not eliminate malignant clones or reliably prevent disease progression.\"}]","Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms - Pathogenic Mechanisms and Therapeutic Opportunities | PDF",1790097715,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/536e7644b84b4851162ae669c8e353ca.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70def74c52c577737734356ee0f44be0.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd5336f160943088ef18bb5aa89b8fad.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9901bce41af8444b648f248ea94540ae.webp",980,1385]